The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Identifying patients potentially cured of mNSCLC with immunotherapy
Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a multi-institutional analysis assessing long-term outcomes in metastatic non-small cell lung cancer (mNSCLC) treated with checkpoint inhibitors. Using a mixture cure model, the study estimated cure rates and evaluated clinical, pathologic, and genomic features of patients with durable benefit. Dual checkpoint blockade was linked with higher proportions of potentially cured patients, while tumor mutational burden and FLT4 alterations emerged as potential predictive biomarkers of long-term benefit. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the big questions in the immunotherapy era in lung cancer is whether we are actually achieving a cure in any of our patients. Increasingly with immunotherapy, we do see some patients with durable long-term responses. And so we were interested in seeing, could we estimate whether any of these people are actually cured? We used a statistical model to do this. In a way, this is just looking at durable long-term responses...
One of the big questions in the immunotherapy era in lung cancer is whether we are actually achieving a cure in any of our patients. Increasingly with immunotherapy, we do see some patients with durable long-term responses. And so we were interested in seeing, could we estimate whether any of these people are actually cured? We used a statistical model to do this. In a way, this is just looking at durable long-term responses. And we found that, you know, a small percentage of our patients are actually achieving durable, stable disease over many years. So whether this is truly a cure, I think, remains to be seen. But we’re kind of hoping that we are seeing actual cures for our metastatic lung cancer patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
